Objective: Hereditary multiple osteochondromas (HMO) usually presents with neoplastic lesions throughout the skeletal system. These lesions frequently cause chronic pain and are conventionally treated with surgical resection and medication. In cases where conventional treatments have failed, spinal cord stimulation (SCS) could be considered as a potential option for pain relief. The objective of this case was to determine if SCS may have a role in treating pain secondary to neoplastic lesions from HMO. Case presentation: We report a 65-year-old female who previously received both surgical and pharmacological interventions for treating HMO neoplastic pain in the lumbar, pelvis, femur, and tibial regions. These interventions either failed to offer significant pain relief or caused excessive lethargy. A SCS trial was then offered with a dual 16-contact lead trial leading to 70%-80% improvement in pain from baseline and 85% reduction in oxycodone IR intake. This was followed by permanent implantation of two 2×8 contact paddle leads (T7-T8 and T9-T10 interspaces). After 8-week follow-up, settings were further optimized resulting in an additional 30% improvement in pain compared to last visit. At 6-month follow-up, the patient reported continued pain relief. Conclusion: This case demonstrates the first successful use of SCS to treat both HMO and nonmalignant neoplastic-related pain. The patient reported pain improvement from baseline, reduced pain medication requirements, and subjective improvement in quality of life. Additionally, this case demonstrates the potential advantage of trialing multiple painful areas with a 16-contact lead in order to avoid multiple trials and placement.
Introduction
Hereditary multiple osteochondromas (HMO) is primarily an autosomal dominant disorder where benign osteochondromas form throughout the skeletal system. Common locations of formation are the metaphyses of long bones including the femur, tibia, and humerus. 1 This rare disorder has a prevalence of one in 50,000 with nearly all patients diagnosed before the age of 12 years. 2, 3 Treatment is recommended when lesions become symptomatic with manifestations of pain, peripheral nerve impingement, or debilitating bone deformities. 4 In most cases, surgical excision is the main treatment although recurrence rates are high, especially with incomplete resection or in rare cases of malignant transformation. 5, 6 Although historically HMO is never treated, spinal cord stimulation (SCS) has been shown to provide symptomatic pain relief for refractory anginal pain, ischemic
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Mirpuri et al pain secondary to peripheral vascular disease, peripheral neuropathic pain, failed back surgery syndrome, and complex regional pain syndrome. 7, 8 SCS is postulated to work through multiple mechanisms including attenuation of dorsal horn neuronal hyperactivity, increased GABA neurotransmitter release, and activation of descending pain-controlling pathways. 9, 10 In a recent 2013 Cochrane Review, the benefits of SCS for neoplastic conditions were evaluated and determined inconclusive, despite several studies demonstrating significant pain relief. 11 Currently, the effectiveness of SCS on neoplastic-mediated pain is still being researched and requires more evidence. We present a case where SCS was successfully used to treat pain from osteochondromas. To our knowledge, this is one of the first reports of nonmalignant bone pain successfully treated with SCS.
Case presentation
A 65-year-old female with a past medical history of HMO presented to the outpatient pain clinic with a 4-year history of back and bilateral leg pain. Patient consent was obtained and de-identified data was utilized for this case report. The pain was characterized as constant, heavy, and aching in nature with an intermittent stabbing component that radiated from the back into her lower extremities. Isolated aching pain was also identified in the left hip, bilateral knees, and bilateral ankles. Pain was assessed using a numeric pain scale of 0-10 with 0 reflecting no pain, 1-3 reflecting mild pain and mild interference on activities of daily living (ADL), 4-6 reflecting moderate pain and moderate interference on ADL, and 7-10 reflecting severe pain and inability to perform ADL. The patient initially reported an average pain of 5/10 and reaching a maximum pain of 9/10. Exacerbating factors included walking, exercise, spinal flexion, and rotation. On physical examination, the patient presented with multiple tender points in the lumbar paraspinals, hips, and ankles. There were palpable osteochondromas in the region of the distal tibias along with pretibial allodynia extending inferiorly to the medial malleoli bilaterally. Motor strength was 5/5 in all extremities, and there was no noted sensory deficit.
Lumbar MRI demonstrated an L5-S1 posterior fusion (previously performed 3 years ago to treat suspected Bertolotti's syndrome), moderate L2-L3 facet arthritis, and no significant central canal or neural foraminal stenosis. The patient's prior fusion provided minimal axial back pain relief and no effect in the lower extremities making Bertolotti's syndrome an unlikely cause for the pain. Electrodiagnostic studies showed mild demyelination of the left common peroneal nerve across fibular head and no evidence of lumbar radiculopathy. Further lower extremity radiographs demonstrated left pelvic, right distal femur, right proximal tibia, and left proximal tibia osteochondromas. Surgical excision was then performed for all the osteochondromas with minimal resolution of symptoms. Follow-up X-rays were repeated approximately a year later and showed new bilateral distal tibia osteochondromas of the metadiaphsysis region. Further surgery was declined, and the patient received numerous interventional pain procedures for various presentations including lumbar epidural steroid injections, ischial bursa injections, and bilateral piriformis injections. The pain was pharmacologically managed with methadone 5 mg three times daily, methocarbamol 750 mg four times daily, and oxycodone immediate release with an average daily consumption of 30-35 mg for breakthrough pain. Multiple neuropathic medications and higher doses of methadone were trialed in the past but discontinued secondary to excess sedation.
The patient subsequently was referred for a trial of SCS. Two 16-contact leads were percutaneously placed under fluoroscopy spanning the right and left of T7-T9 vertebral bodies (Figure 1 ). Settings for both leads were optimized at an amplitude of 5.2 mA, pulse width of 210 µS, and frequency of 40 Hz. The patient was discharged home for 5 days with the trial leads and reported 70%-80% improvement in pain and 85% reduction in oxycodone IR intake. The patient was then scheduled for permanent implantation with two 2×8 contact paddle leads and an implantable pulse generator that can accommodate 32 contacts. The patient was taken to the operating room under general anesthesia where a T8-T9 hemilaminectomy was performed and two longitudinal paddle leads were placed overlying areas of the T7-T8 and T9-T10 interspaces (Figure 2) . The two paddle leads were utilized in order to cover pain from the back, hip, and ankles. The T7-T8 paddle lead was programmed to an amplitude of 2.6 mA, pulse width of 290 µS, and frequency of 40 Hz. The T9-T10 paddle lead was set to an amplitude of 4.1 mA, pulse width of 470 µS, and frequency of 40 Hz. On 8-week follow-up, settings were adjusted, and the patient reported another 30% reduction in pain compared to last visit's baseline, complete discontinuation of methadone, and increased ADL such as being able to climb steps more easily. At 6-month follow-up, the patient reported continued relief.
Written informed consent was obtained from our patient for publication of this case report and any accompanying images. Institutional Review Board was not needed for this study since it was a retrospective analysis of a single case.
Discussion
We report the first case to our knowledge of a SCS being used successfully to treat multifactorial pain mediated by HMO. In this particular case, the pain was likely mediated by failed back syndrome, direct contact on the capsular joints, bone-mediated pain, and a mass effect on the surrounding soft tissue. Both the trial and the permanent implant phases of SCS were successfully able to reduce her overall pain intensity, improve her quality of life, and reduce her narcotic medication requirements.
Due to pain in multiple regions, this particular case illustrates the utility of being able to use a 16-contact lead compared to an eight-contact lead during a single trial. By spanning across 2.5 vertebral levels with closer contacts, we were theoretically allowed broader spinal cord coverage to better target the back, hip, and ankles. We would recommend that physicians who treat multiregional neoplastic pain with SCS consider this multilevel approach in order to accommodate 1) more dynamic pain patterns and 2) reduce the need for a staggered single lead coverage trial over multiple pain areas. 12, 13 However, further studies certainly are needed to prove whether this approach is more efficacious clinically and not just theoretical.
After performing a MEDLINE search, we were unable to identify any other cases of treating nonmalignant neoplastic bone pain with SCS. However, cancer-related neoplasms have been treated successfully in a manner similar to our case. 11, 14 Of note, Yakovlev and Resch reported using SCS to treat 15 patients with cancer-related back pain all of whom showed significant improvement. 15 Additionally, there are several spinal metastasis case reports indicating improvement after similar treatment. 16, 17 In general, past review articles have rarely discussed SCS as an indication to treat neoplastic-mediated pain. 18 This is likely due to the fact that no randomized controlled trials have been published concerning this scenario. Further research should be considered in treating neoplastic-mediated pain that has been resistant to both pharmacological and surgical modalities with SCS.
